MapLight Therapeutics (MPLT) Share-based Compensation (2024 - 2025)
MapLight Therapeutics (MPLT) reported Share-based Compensation of $35.5 million for Q4 2025, up 5638.45% on a YoY basis from $619000.0 in Q4 2024, and up 28316.8% sequentially from $125000.0 in Q3 2025.
MapLight Therapeutics (MPLT) Share-based Compensation (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Share-based Compensation data on file, last reported at $35.5 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 5638.45% year-over-year to $35.5 million; the trailing twelve-month figure through Dec 2025 stood at $36.6 million (changed N/A YoY), and the FY2025 full-year result was $38.2 million, up 2472.39% from the prior year.
- Share-based Compensation rose to $35.5 million in Q4 2025, from $125000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $35.5 million in Q4 2025 to a low of $125000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 35.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.52 Mn |
| Dec 31, 2025 | 35.52 Mn |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Dec 31, 2024 | 619,000.00 |
| Dec 31, 2024 | 619,000.00 |
| Sep 30, 2024 | 354,000.00 |
| Sep 30, 2024 | 354,000.00 |